The activity of mitomycin in non-small cell lung cancer (NSCLC) has been well documented in both single-institution pilot and multi-institution randomized trials. Despite the inclusion of patients ineligible for current trials of newer single agents due to poor performance status, prior irradiation to indicator lesions, or prior chemotherapy, mitomycin emerges from such prior studies as the most consistently active single agent currently available for NSCLC. While randomized trials in stage IV disease demonstrate an improved response rate with mitomycin and cisplatin in comparison with cisplatin alone (p = 0.03), and with mitomycin, vindesine, and cisplatin in comparison with vindesine and cisplatin alone (p = 0.003), the potential with mitomycin is most apparent with weekly bolus or infused vindesine/vinblastine, and higher-dose cisplatin (MVP) in neoadjuvant approaches to stage III disease. Indeed, four trials of neoadjuvant MVP in predominantly stage IIIA (bulky N2) disease produced a consistent 19-month median and 26–33% 3-year survival, which is to be compared with 8 months and 6%, respectively, with traditional thoracic irradiation alone. Nonetheless, prior use of mitomycin without guidelines for cumulative dose, schedule, or guidelines for use in combined-modality therapy has produced widespread frustration stemming not only from frequent antineoplastic effect, but also from frequent toxicity. The several related syndromes of mitomycin-associated thrombotic microangiopathy, ranging from hemolytic-uremic syndrome to pulmonary injury, appear avoidable through limiting the cumulative mitomycin dose to a maximum of 30 mg/m2; scheduling mitomycin at not less than 4– to 6-week intervals; perioperative use of corticosteroids and low inspired oxygen; and close patient follow-up. While dexamethasone preceding mitomycin reduces the frequency and severity of mitomycin-associated lung injury (p = 0.0005), dexamethasone premedication also reduces the response rate of MVP in NSCLC (p < 0.025).

Keywords:
Mitomycin, Non-small cell lung cancer, Mitomycin in combined-modality therapy, Mitomycin-associated toxicity, Avoidance of mitomycin-associated toxicity
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.